David Zaccardelli, Verona Pharma CEO
January 2, 2024 05:56 AM ESTUpdated 06:37 AM
Financing
R&D

Verona se­cures $400M fi­nanc­ing arrange­ment with Ox­ford, Her­cules as en­sifen­trine PDU­FA date inch­es clos­er

Ayisha Sharma

News Reporter

Verona Phar­ma has inked a debt fi­nanc­ing deal worth up to $400 mil­lion with Ox­ford Fi­nance and Her­cules Cap­i­tal as it pre­pares for the po­ten­tial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times